Serving as embedded Entrepreneur-in-Residence to a grant-funded university research program developing textile-based biosensors, covering FDA regulatory pathway, business model, and capital formation across a 24-month engagement.
University Research Program
7/21/2026
A university team had a genuinely novel sensing technology and a 24-month grant, but no regulatory pathway, no business model, and no clear route from a research prototype to a product anyone could buy or a company anyone would fund.
An embedded Entrepreneur-in-Residence role covering FDA regulatory strategy from wellness-device clearance through a software-as-a-medical-device transition, alongside customer discovery, business model development, and funding roadmap.
Our Role
Engagement
Regulatory Path
Status
A university research program is developing textile-based biosensors: conductive material embroidered or woven into fabric, capturing biosignals through something a person would wear anyway. The target applications are sleep staging and early detection of neurodegenerative conditions, both of which currently require equipment that changes the behavior being measured.
The science is strong and grant-funded for two years. What the program did not have was a route from prototype to product. We serve as embedded Entrepreneur-in-Residence for the duration of the grant.
Client: A grant-funded research program at a university, developing wearable biosensing technology.
Engagement: Embedded Entrepreneur-in-Residence across the 24-month grant period, working alongside the principal investigator and research team. Ongoing.
Academic research programs and medical device companies optimize for different things. A research program is rewarded for novelty and publication. A device company is rewarded for a cleared, reimbursable, manufacturable product. The gap between them is where most promising university technology stalls.
The specific risk here is sequencing. Regulatory requirements shape what evidence the technical work must generate, and a program that designs its studies without reference to a submission pathway will generate the wrong evidence and discover it late, when the grant is spent and the data cannot be regenerated.
We made regulatory pathway the highest-priority workstream, ahead of business model and go-to-market, for the reason above: it constrains everything else.
The strategy is two-stage. The first stage is a Class II clearance for a wellness device, which requires identifying suitable predicate devices and establishing equivalence. The second is a transition to software-as-a-medical-device classification, which is what clinical diagnostic claims require and which carries a substantially heavier evidence burden.
Sequencing these matters. A wellness clearance is achievable inside the grant period and produces a real product; going straight for diagnostic claims would not be. It also means the program can generate revenue and evidence in parallel rather than waiting for the harder clearance.
Concrete work here covers predicate device analysis, a regulatory roadmap with decision gates and FDA interaction points, biocompatibility testing requirements for the conductive electrode material, verification and validation test planning, the software lifecycle compliance the eventual classification will demand, pre-submission meeting strategy, clinical study design for predicate equivalence, and a quality management system framework.
Running alongside the regulatory work: a business model addressing the three plausible routes to market, which are clinical B2B, consumer wellness, and licensing the platform. These have different economics and different evidence requirements, and the program cannot pursue all three.
Customer discovery is structured across the segments that would actually buy, spanning sleep clinics, neurologists, research laboratories, and at-home users, with competitive analysis against traditional instrumentation, emerging wearables, and dry-electrode approaches. The value proposition to validate is specific: whether comfort and the absence of behavior change genuinely outweigh whatever signal quality is given up relative to clinical equipment.
The grant is a runway, not a destination. The funding roadmap sequences non-dilutive sources through institutional rounds, with the milestones each stage requires. Alongside it, the organizational work a research program eventually cannot avoid: which roles must be hired, what a scientific and clinical advisory board should look like, which partnerships matter, and how entity formation and IP assignment should be handled.
The engagement is ongoing across the grant period. The near-term milestones are predicate analysis, an initial customer discovery cohort, and a drafted regulatory roadmap; the later ones move toward validation test planning, funding applications, and the software-as-a-medical-device classification plan.
Client identity, technology specifics, and grant details are withheld under confidentiality.
